FRAMINGHAM, MA--(Marketwire - May 16, 2008) - The GI Company, Inc., a privately held developer of gastrointestinal therapeutics, today reported that the American Society of Clinical Oncology (ASCO) published an abstract containing a compelling data summary from a Phase II clinical study designed to evaluate the safety and efficacy of the company’s lead clinical compound, Intestinal Trefoil Factor (rhITF). The GI Company’s study abstract (ID: 9514 / 2006 - ITF - 009) is titled, “Prophylaxis of recurrent chemotherapy-induced oral mucositis: A Phase II multicenter, randomized, placebo-controlled trial of recombinant human Intestinal Trefoil Factor (rhITF).”
